Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease

Wael El-Matary, Esmail Abej, Vini Deora, Harminder Singh, Charles N Bernstein, Wael El-Matary, Esmail Abej, Vini Deora, Harminder Singh, Charles N Bernstein

Abstract

Background: The use of fecal calprotectin (FCal) as a marker of intestinal inflammation, in the management of inflammatory bowel disease (IBD) is increasing. The aim of this study was to examine the impact of FCal measurements on decision-making and clinical care of children with IBD.

Materials and methods: In a retrospective cohort study, FCal, clinical activity indices, and blood markers were measured in children with established diagnoses of IBD. Pearson correlation coefficient analysis was performed to examine association between FCal and other markers. Decisions based on FCal measurements were prospectively documented and participants were evaluated 3-6 months later.

Results: A total of 115 fecal samples were collected from 77 children with IBD [median age 14, interquartile range (IQR) 11-15.6 years, 42 females, 37 with Crohn's disease]. FCal positively correlated with clinical activity indices (r = 0.481, P < 0.05) and erythrocyte sedimentation rate (r = 0.40, P < 0.05) and negatively correlated with hemoglobin (r = -0.40, P < 0.05). Sixty four out of 74 (86%) positive FCal measurements (≥250 μg/g of stools) resulted in treatment escalation with subsequent significant clinical improvement while in the FCal negative group, 34 out of 41 (83%) measurements resulted in no change in treatment and were associated with remission on follow-up.

Conclusion: Based on high FCal, the majority of children had treatment escalation that resulted in clinical improvement. FCal measurements were useful and reliable in decision-making and clinical care of children with IBD.

Keywords: Crohn; IBD; calprotectin; children; colitis.

Figures

Figure 1
Figure 1
Flow chart summarizing the impact of fecal calprotectin measurements on the decision-making process among children with inflammatory bowel disease.

References

    1. Sherwood RA. Faecal markers of gastrointestinal inflammation. J Clin Pathol (2012) 65:981–5.10.1136/jclinpath-2012-200901
    1. Abraham BP, Kane S. Fecal markers: calprotectin and lactoferrin. Gastroenterol Clin North Am (2012) 41:483–95.10.1016/j.gtc.2012.01.007
    1. Foell D, Wittkowski H, Roth J. Monitoring disease activity by stool analyses: from occult blood to molecular markers of intestinal inflammation and damage. Gut (2009) 58:859–68.10.1136/gut.2008.170019
    1. Judd TA, Day AS, Lemberg DA, Turner D, Leach ST. Update of fecal markers of inflammation in inflammatory bowel disease. J Gastroenterol Hepatol (2011) 26:1493–9.10.1111/j.1440-1746.2011.06846.x
    1. Rocchi A, Benchimol EI, Bernstein CN, Bitton A, Feagan B, Panaccione R, et al. Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 26:811–7.10.1155/2012/984575
    1. Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R, et al. Challenges in pediatric inflammatory bowel disease. Inflamm Bowel Dis (2006) 12:885–913.10.1097/01.mib.0000228358.25364.8b
    1. El-Matary W, Dupuis K, Sokoro A. Anti-Saccharomyces cerevisiae antibody titres correlate well with disease activity in children with Crohn’s disease. Acta Paediatr (2015) 104:827–30.10.1111/apa.13026
    1. Guardiola J, Lobatón T, Rodríguez-Alonso L, Ruiz-Cerulla A, Arajol C, Loayza C, et al. Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission. Clin Gastroenterol Hepatol (2014) 12:1865–70.10.1016/j.cgh.2014.06.020
    1. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis (2008) 14:40–6.10.1002/ibd.20490
    1. De Vos M, Dewit O, D’Haens G, Baert F, Fontaine F, Vermeire S, et al. Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF naïve patients with ulcerative colitis. J Crohns Colitis (2012) 6:557–62.10.1016/j.crohns.2011.11.002
    1. IBD Working Group of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr (2005) 41:1–7.10.1097/01.MPG.0000163736.30261.82
    1. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, et al. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology (2007) 133:423–32.10.1053/j.gastro.2007.05.029
    1. Hyams JS, Ferry GD, Mandel FS, Gryboski JD, Kibort PM, Kirschner BS, et al. Development and validation of a pediatric Crohn’s disease activity index. J Pediatr Gastroenterol Nutr (1991) 12:439–47.10.1097/00005176-199105000-00005
    1. Griffiths AM, Otley AR, Hyams J, Quiros AR, Grand RJ, Bousvaros A, et al. A review of activity indices and end points for clinical trials in children with Crohn’s disease. Inflamm Bowel Dis (2005) 11:185–96.10.1097/00054725-200502000-00013
    1. Abej E, El-Matary W, Singh H, Bernstein CN. The utility of fecal calprotectin in the real-world clinical care of patients with inflammatory bowel disease. Can J Gastroenterol Hepatol (2016) 2016:2483261.
    1. Alibrahim B, Aljassar MI, Slah B. Fecal calprotectin use in inflammatory bowel disease and beyond: a mini-review. Can J Gastroenterol Hepatol (2015) 29:157–63.10.1155/2015/950286
    1. D’Haens G, Ferrante M, Vermeire S, Baert F, Noman M, Moortgat L, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 18:2218–24.10.1002/ibd.22917
    1. Bunn SK, Bisset WM, Main MJC, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr (2001) 32:171–7.10.1097/00005176-200102000-00015
    1. Canani RB, Terrin G, Rapaccioulo L, Miele E, Siani MC, Puzone C, et al. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis (2008) 40:547–53.10.1016/j.dld.2008.01.017
    1. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, et al. Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol (2010) 105:162–9.10.1038/ajg.2009.545
    1. Schoepfer AM, Beglinger C, Straumann A, Safroneeva E, Romero Y, Armstrong D, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis (2013) 19:332–41.10.1097/MIB.0b013e3182810066
    1. Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut (2005) 54:364–8.10.1136/gut.2004.043406
    1. van Rheenen PF. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control. Inflamm Bowel Dis (2012) 18:2018–25.10.1002/ibd.22896
    1. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, et al. Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut (2010) 59:1207–12.10.1136/gut.2010.211755
    1. Eccles J, Neely A, Lynch M, Ferguson CB, Morrison G. An overview of the impact of fecal calprotectin testing in the management of patients within the gastroenterology outpatient clinic in a general hospital. Gastroenterology (2014) 146(Suppl 1):S–798.10.1016/S0016-5085(14)62888-2
    1. Osterman MT, Aberra FN, Cross R, Liakos S, McCabe R, Shafran I, et al. Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol (2014) 12:1887–93.10.1016/j.cgh.2014.03.035
    1. Lasson A, Öhman L, Stotzer PO, Isaksson S, Überbacher O, Ung KA, et al. Pharmacological intervention based on fecal calprotectin levels in patients with ulcerative colitis at high risk of a relapse: a prospective, randomized, controlled study. United European Gastroenterol J (2015) 3:72–9.10.1177/2050640614560785

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren